Protocols›Metabolic & fat loss›Oral GLP-1 · Foundayo
← Protocols
Oral · once-dailyNeedle-free · GLP-1 entryFDA-approved (US)

Oral GLP-1 · Foundayo

Stack: Orforglipron · the needle-free, once-daily entry to the incretin class
"The injection-free counterpart to the GLP-1 Foundation. Orforglipron (Foundayo) is a small-molecule GLP-1 pill — FDA-approved in April 2026, taken once daily with no food or water rules. Like semaglutide, the honest issue isn't whether it works; it's that it's prescription-only, carries a boxed thyroid warning, and isn't UK-approved yet."
GoalWeight loss / glycaemic control · oral
Compounds1 · Orforglipron
Human evidenceStrong — Phase 3 (ATTAIN / ACHIEVE)
StatusFDA (US): approved 1 Apr 2026 (Foundayo) — prescription only · MHRA (UK): not yet approved. Any UK supply ahead of approval is outside the licensed chain, and a pill is easy to counterfeit
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Approved clinical use (US)
Where / who
FDA-approved on 1 April 2026 as Foundayo for chronic weight management in adults with obesity, or overweight with a weight-related condition — alongside diet and activity.
Status
A fully approved US medicine with an approved label and pharmacovigilance — the opposite of a research compound. Not yet approved in the UK.
Evidence it adds
Regulator-grade efficacy and safety — for the licensed product, used as directed.
Basis: FDA approval (Foundayo, Apr 2026)
Clinical trial evidence
Weight
The ATTAIN programme: roughly 11% mean weight loss at the higher doses over 72 weeks — meaningful, though generally below peak injectable figures.
Glycaemic
ACHIEVE (type 2 diabetes); a head-to-head in The Lancet had oral orforglipron beat oral semaglutide on both glucose and weight.
Evidence it adds
Controlled Phase 3 human efficacy and safety data — the strongest tier in this catalogue.
Basis: ATTAIN, ACHIEVE, Lancet head-to-head
Grey-market / unsupervised use
Where / who
Ahead of UK approval, some will source it outside any prescription. A swallowed small-molecule tablet is comparatively easy to counterfeit convincingly.
What changes
Supervision, dose titration and — critically — product identity are no longer controlled. An unverified pill cannot be confirmed for identity or dose.
Evidence it adds
None on efficacy — this layer is about how unsupervised use diverges from the trials.
Basis: real-world sourcing patterns — not a trial tier
Regulatory — read carefully
MHRA (UK)
Not yet approved. There is no UK marketing authorisation for orforglipron at time of writing — so there is no licensed UK route, and any supply here is unlicensed.
FDA (US)
Approved 1 Apr 2026, prescription-only. Carries a boxed warning for thyroid C-cell tumours (MTC); contraindicated with personal/family history of MTC or MEN-2.
What it means
Approved in the US does not mean available or lawful to source in the UK — and the safety record belongs to the prescribed product.
Basis: FDA approval · boxed warning · no MHRA authorisation
Why this is the foundation

Orforglipron is the needle-free way into the GLP-1 class. Because it is a non-peptide small molecule, it survives the gut and works as an ordinary once-daily tablet — taken any time of day, with or without food or water, unlike the strict rules oral semaglutide needs. The trade-off is that peak weight loss (~11% in ATTAIN) generally sits below the strongest injectables. The honest framing matches the injectable Foundation: the question isn't whether it works, it's whether it's run the way the evidence was generated — prescribed, titrated and supervised — or sourced as an unverified pill, in a market where it isn't UK-approved yet.

Members only · the actionable depth
See exactly how it's run
Doses, titration structure and what to monitor are part of membership. The provenance, evidence and status above are always free.
Get the tracker · £4.99/mo →
£4.99/mo · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Titration
0.8 mg → up, ≥30-day steps
Maintenance
effective dose (max 17.2 mg)
Review
continue / adjust
The FDA label starts at 0.8 mg once daily and steps up no faster than every 30 days (2.5 → 5.5 → 9 → 14.5 → 17.2 mg) to manage GI side-effects — this mirrors the licensed schedule, not a prescription to follow.
What's worth monitoring

Orforglipron has a defined clinical monitoring picture: GI tolerance during titration; a boxed thyroid C-cell warning (contraindicated with personal/family history of MTC or MEN-2); muscle-mass loss alongside fat loss; and CYP3A4 drug interactions (max 9 mg with a strong inhibitor). It's a CYP3A4 substrate, so review concomitant medicines. The licensed product is monitored by a prescriber; outside that route, no one is — and in the UK there is no licensed route yet. Baseline bloods and a clinician conversation are the sensible floor. General information, not medical advice.

Evidence
Human efficacy Strong

Phase 3 (ATTAIN / ACHIEVE) — ~11% mean weight loss over 72 weeks; beat oral semaglutide head-to-head in T2D.

Approval Strong

FDA-approved 1 Apr 2026 (Foundayo) — approved label and pharmacovigilance. UK: not yet approved.

Unsupervised use Risk shifts

A pill is easy to counterfeit; an unverified tablet can't be confirmed for identity or dose — and it isn't UK-approved.

The honest point

Proven and US-approved. The harm-reduction question is the supply route — and, in the UK, the missing licence.

Fast facts
Compounds

Orforglipron

Brand

Foundayo (Eli Lilly)

UK strip

AMBER — POM · not yet UK-approved